Craft
Corestem

Corestem

Revenue

₩30.2 B

FY, 2021

Corestem Summary

Company summary

Overview
Corestem (코아스템) is a biopharmaceutical company that researches and commercializes stem cell technology. It provides NEURONATA-R, a stem cell therapy for amyotrophic lateral sclerosis. In addition, the company focuses on lupus, multiple system atrophy, and osteoarthritis.
Type
Public
Status
Active
Founded
2003
HQ
Seongnam-si, KR | view all locations
Website
http://www.corestem.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

LocationsView all

1 location detected

  • Seongnam-si, Gyeonggi-do HQ

    Korea (Republic of)

    Pangyo-ro, Bundang-gu

Corestem Financials

Summary financials

Revenue (Q2, 2022)
₩14.2B
Gross profit (Q2, 2022)
₩12.2B
Net income (Q2, 2022)
₩6.0B
Cash (Q2, 2022)
₩7.9B
EBIT (Q2, 2022)
₩2.2B

Footer menu